These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 7728133

  • 1. Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation.
    Blume KG, Long GD, Negrin RS, Chao NJ, Kusnierz-Glaz C, Amylon MD.
    Bone Marrow Transplant; 1994; 14 Suppl 4():S9-10. PubMed ID: 7728133
    [Abstract] [Full Text] [Related]

  • 2. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
    Long GD, Amylon MD, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW, Nademanee AP, Snyder DS, Hoppe RT, Vora N, Wong R, Niland J, Reichardt VL, Forman SJ, Blume KG.
    Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
    [Abstract] [Full Text] [Related]

  • 3. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study.
    Blume KG, Kopecky KJ, Henslee-Downey JP, Forman SJ, Stiff PJ, LeMaistre CF, Appelbaum FR.
    Blood; 1993 Apr 15; 81(8):2187-93. PubMed ID: 8471778
    [Abstract] [Full Text] [Related]

  • 4. Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
    Wu DP, Milpied N, Moreau P, Mechinaud-Lacroix F, Mahe B, Le Tortorec S, Rapp MJ, Bourdin S, Mahe JM, Harousseau JL.
    Bone Marrow Transplant; 1994 Nov 15; 14(5):751-7. PubMed ID: 7889008
    [Abstract] [Full Text] [Related]

  • 5. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
    Duerst RE, Horan JT, Liesveld JL, Abboud CN, Zwetsch LM, Senf ES, Constine LS, Raubertas RF, Passarell JA, DiPersio JF.
    Bone Marrow Transplant; 2000 Mar 15; 25(5):489-94. PubMed ID: 10713624
    [Abstract] [Full Text] [Related]

  • 6. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.
    Vaughan WP, Dennison JD, Reed EC, Klassen L, McGuire TR, Sanger WG, Kumar PP, Warkentin PI, Gordon BG, Bierman PJ.
    Bone Marrow Transplant; 1991 Dec 15; 8(6):489-95. PubMed ID: 1790429
    [Abstract] [Full Text] [Related]

  • 7. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan 15; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of etoposide, cyclophosphamide, and total body irradiation in allogeneic bone marrow transplantation for adult patients with hematological malignancies.
    Toubai T, Tanaka J, Mori A, Hashino S, Kobayashi S, Ota S, Miura Y, Kato N, Kahata K, Izumiyama K, Yonezumi M, Chiba K, Kondo T, Toyoshima N, Asaka M, Imamura M.
    Clin Transplant; 2004 Oct 15; 18(5):552-7. PubMed ID: 15344959
    [Abstract] [Full Text] [Related]

  • 9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 15; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 10. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
    Zander AR, Berger C, Kröger N, Stockshläder M, Krüger W, Horstmann M, Grimm J, Zeller W, Kabisch H, Erttmann R, Schönrock P, Kuse R, Braumann D, Illiger HJ, Fiedler W, de Witt M, Hossfeld KD, Weh HJ.
    Clin Cancer Res; 1997 Dec 15; 3(12 Pt 2):2671-5. PubMed ID: 10068272
    [Abstract] [Full Text] [Related]

  • 11. Can busulfan replace fractionated total body irradiation as conditioning regimen for allogeneic bone marrow transplantation in children with acute lymphoblastic leukemia.
    Wachowiak J, Bettoni C, Lange A, Malicki J, Kaczmarek-Kanold M, Głuszak B, Suchnicki K, Daszkiewicz P, Ebell W.
    Acta Haematol Pol; 1995 Dec 15; 26(4):377-84. PubMed ID: 8571739
    [Abstract] [Full Text] [Related]

  • 12. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F, Copelan E, Crilley P, Bolwell B, Avalos B, Klein J, Territo M, Gajewski J.
    Bone Marrow Transplant; 1996 May 15; 17(5):685-9. PubMed ID: 8733682
    [Abstract] [Full Text] [Related]

  • 13. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
    Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Obara M, Wakasa K, Takahata M, Takeda Y, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M.
    Biol Blood Marrow Transplant; 2008 May 15; 14(5):568-75. PubMed ID: 18410899
    [Abstract] [Full Text] [Related]

  • 14. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
    Jillella AP, Doria R, Khan K, Zelterman D, Ahmad YH, Smith BR, Holmes W, Becker P, Roberts KB, Rappeport JM.
    Bone Marrow Transplant; 1999 Jun 15; 23(11):1095-100. PubMed ID: 10382947
    [Abstract] [Full Text] [Related]

  • 15. Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: lack of superiority over cyclophosphamide-containing conditioning regimens.
    Woods WG, Ramsay NK, Weisdorf DJ, Haake R, Vallera DA, Kim TH, Lasky L, Nesbit ME, Bostrom B, Uckun F.
    Bone Marrow Transplant; 1990 Jul 15; 6(1):9-16. PubMed ID: 2202462
    [Abstract] [Full Text] [Related]

  • 16. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma.
    Stockerl-Goldstein KE, Horning SJ, Negrin RS, Chao NJ, Hu WW, Long GD, Hoppe RT, Amylon MD, Brown BW, Wong RM, Blume KG.
    Biol Blood Marrow Transplant; 1996 May 15; 2(2):76-85. PubMed ID: 9118302
    [Abstract] [Full Text] [Related]

  • 17. Treatment of infant leukemia with busulfan, cyclophosphamide +/- etoposide and bone marrow transplantation.
    Emminger W, Emminger-Schmidmeier W, Haas OA, Urban C, Ambros P, Peters C, Mann G, Fink FM, Ferstl G, Höcker P.
    Bone Marrow Transplant; 1992 May 15; 9(5):313-8. PubMed ID: 1617314
    [Abstract] [Full Text] [Related]

  • 18. Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies.
    Crilley P, Lazarus H, Topolsky D, Ciobanu N, Creger RJ, Fox RM, Bulova SI, Shina DC, Gucalp R, Cooper BW.
    Semin Oncol; 1993 Aug 15; 20(4 Suppl 4):50-4; quiz 55. PubMed ID: 8342076
    [Abstract] [Full Text] [Related]

  • 19. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR.
    Bone Marrow Transplant; 2000 Oct 15; 26(7):711-6. PubMed ID: 11042650
    [Abstract] [Full Text] [Related]

  • 20. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S, Bishop MR, Tarantolo S, Cowles MK, Reed E, Anderson JR, Vose JM, Bierman P, Armitage JO, Kessinger A.
    Exp Hematol; 1995 Dec 15; 23(14):1503-8. PubMed ID: 8542938
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.